|
1
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosner MH, Vigano MA, Ozato K, Timmons PM,
Poirier F, Rigby PW and Staudt LM: A POU-domain transcription
factor in early stem cells and germ cells of the mammalian embryo.
Nature. 345:686–692. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ,
Gimotty PA, Guerra M, Guo W and Xu X: Acquired cancer stem cell
phenotypes through Oct4-mediated dedifferentiation. Oncogene.
31:4898–4911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeter CR, Yang T, Wang J, Chao HP and Tang
DG: Concise review: NANOG in cancer stem cells and tumor
development: An update and outstanding questions. Stem Cells.
33:2381–2390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chambers I, Colby D, Robertson M, Nichols
J, Lee S, Tweedie S and Smith A: Functional expression cloning of
Nanog, a pluripotency sustaining factor in embryonic stem cells.
Cell. 113:643–655. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Savage P: Chemotherapy curable
malignancies and cancer stem cells: A biological review and
hypothesis. BMC Cancer. 16:9062016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen H, Xu C, Jin Q and Liu Z: S100
protein family in human cancer. Am J Cancer Res. 4:89–115.
2014.PubMed/NCBI
|
|
8
|
Bresnick AR, Weber DJ and Zimmer DB: S100
proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marenholz I and Heizmann CW: S100A16, a
ubiquitously expressed EF-hand protein which is up-regulated in
tumors. Biochem Biophys Res Commun. 313:237–244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou W, Pan H, Xia T, Xue J, Cheng L, Fan
P, Zhang Y, Zhu W, Xue Y, Liu X, et al: Up-regulation of S100A16
expression promotes epithelial-mesenchymal transition via Notch1
pathway in breast cancer. J Biomed Sci. 21:972014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Zhang R, Xin J, Sun Y, Li J, Wei D
and Zhao AZ: Identification of S100A16 as a novel adipogenesis
promoting factor in 3T3-L1 cells. Endocrinology. 152:903–911. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abdelalim EM and Tooyama I: Knockdown of
p53 suppresses Nanog expression in embryonic stem cells. Biochem
Biophys Res Commun. 443:652–657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin J, Yang Q, Wilder PT, Carrier F and
Weber DJ: The calcium-binding protein S100B down-regulates p53 and
apoptosis in malignant melanoma. J Biol Chem. 285:27487–27498.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Orre LM, Panizza E, Kaminskyy VO, Vernet
E, Gräslund T, Zhivotovsky B and Lehtiö J: S100A4 interacts with
p53 in the nucleus and promotes p53 degradation. Oncogene.
32:5531–5540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pastrana E, Silva-Vargas V and Doetsch F:
Eyes wide open: A critical review of sphere-formation as an assay
for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei B, Han XY, Qi CL, Zhang S, Zheng ZH,
Huang Y, Chen TF and Wei HB: Coaction of spheroid-derived stem-like
cells and endothelial progenitor cells promotes development of
colon cancer. PLoS One. 7:e390692012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujii H, Honoki K, Tsujiuchi T, Kido A,
Yoshitani K and Takakura Y: Sphere-forming stem-like cell
populations with drug resistance in human sarcoma cell lines. Int J
Oncol. 34:1381–1386. 2009.PubMed/NCBI
|
|
20
|
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK,
Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Naniwa J, Kigawa J, Akeshima R, Kanamori
Y, Itamochi H, Oishi T, Iba T and Terakawa N: Leptomycin B enhances
CDDP-sensitivity via nuclear accumulation of p53 protein in
HPV-positive cells. Cancer Sci. 94:1099–1103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu HM, Liao B, Zhang QJ, Wang BB, Li H,
Zhong XM, Sheng HZ, Zhao YX, Zhao YM and Jin Y: Wwp2, an E3
ubiquitin ligase that targets transcription factor Oct-4 for
ubiquitination. J Biol Chem. 279:23495–23503. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Floyd ZE, Staszkiewicz J, Power RA, Kilroy
G, Kirk-Ballard H, Barnes CW, Strickler KL, Rim JS, Harkins LL, Gao
R, et al: Prolonged proteasome inhibition cyclically upregulates
Oct3/4 and Nanog gene expression, but reduces induced pluripotent
stem cell colony formation. Cell Reprogram. 17:95–105. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vlashi E, Kim K, Lagadec C, Donna LD,
McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W and Pajonk
F: In vivo imaging, tracking, and targeting of cancer stem cells. J
Natl Cancer Inst. 101:350–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka M, Ichikawa-Tomikaw N, Shishito N,
Nishiura K, Miura T, Hozumi A, Chiba H, Yoshida S, Ohtake T and
Sugino T: Co-expression of S100A14 and S100A16 correlates with a
poor prognosis in human breast cancer and promotes cancer cell
invasion. BMC Cancer. 13:532015. View Article : Google Scholar
|
|
28
|
Saito K, Kobayashi M, Nagashio R, Ryuge S,
Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, et
al: S100A16 is a prognostic marker for lung adenocarcinomas. Asian
Pac J Cancer Prev. 16:7039–7044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sapkota D, Bruland O, Parajuli H, Osman
TA, Teh MT, Johannessen AC and Costea DE: S100A16 promotes
differentiation and contributes to a less aggressive tumor
phenotype in oral squamous cell carcinoma. BMC Cancer. 15:6312015.
View Article : Google Scholar : PubMed/NCBI
|
